Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
MBXthis companyMBX Biosciences, Inc. Common Stock	$54.54	-13.25×	3.12×	0×	-12.42×	-96.3%	0.0%	0.0%	0.0%	-23.6%	-26.5%	-7.1%	0×	0.86×	0×	24.62×	0.0%	1	58.99	2	C
ALTAltimmune, Inc.	$2.18	-3.61×	1.41×	7,757.46×	-3.56×	-96.0%	100.0%	-230461.0%	-214861.0%	-39.2%	-35.4%	-21.2%	0.16×	0.09×	-57.76×	18.55×	0.0%	2	2.76	2	C+
BMEABiomea Fusion, Inc.	$0.60	-1.05×	2.19×	0×	-0.17×	48.4%	0.0%	0.0%	0.0%	-209.1%	-166.2%	-108.7%	0.05×	0.9×	0×	5.23×	0.0%	0	-18.95	2	C+
KLRAKailera Therapeutics, Inc.	$13.71	-20.63×	-8.6×	0×	-18.46×	-89.9%	0.0%	0.0%	0.0%	41.8%	-24.5%	-4.0%	-0.03×	0.95×	0×	12.01×	0.0%	—	—	2	C+
LPCNLipocine Inc.	$1.64	-4.54×	3.02×	22.14×	-4.08×	-53.7%	-334.3%	-524.7%	-487.1%	-66.5%	-69.5%	-22.3%	0.03×	0.5×	0×	6.68×	0.0%	2	-9.68	2	C
ORMPOramed Pharmaceuticals Inc.	$3.97	1.86×	0.59×	59×	0.97×	-70.9%	0.7%	-754.4%	3202.5%	32.1%	-6.0%	-9.4%	0×	-0.6×	0×	6.98×	0.0%	3	3.38	5	S-
Peer median	—	-3.61×	1.41×	22.14×	-3.56×	-70.9%	0.0%	-524.7%	0.0%	-39.2%	-35.4%	-21.2%	0.03×	0.5×	0×	6.98×	0.0%	2	-3.46	2	—